SLS-010: Potent Oral H3R Inverse Agonist
Two back-up pre-clinical candidates identified
SLS-9634 and SLS-4414 are structurally distinct from SLS-010
Strong efficacy in animal models
FIH study possible in 9-12 months
SLS-010 is a potent histamine receptor
(H3R) universe agonist
H3R is important in a number of CNS
related diseases such as narcolepsy and
excessive daytime sleepiness
Orally efficacious; good drug-like
physiochemical properties
Pre-clinical ADME &
safety profile acceptable
Good oral exposure in rats/dogs/monkeys
FIH study possible in 5-6 months
SLS-010 and back-ups have best-in-class profiles
Ideally suited for oral QD in narcolepsy and excessive day time sleepiness